News AC Immune SA

Equities

ACIU

CH0329023102

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
2.52 ^USD	-8.03%		-10.00%	-49.60%

Mar. 15	AC Immune Files $350 Million Mixed Shelf	MT
Mar. 14	AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AC Immune Files $350 Million Mixed Shelf	Mar. 15	MT
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update	Mar. 14	AQ
AC Immune Announces Upcoming Presentations at AD/PD™ 2024	Feb. 22	AQ
Certain Common Shares of AC Immune SA are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
AC Immune to Regain Global Rights of Crenezumab, Semorinema	Jan. 22	MT
Roche terminates licensing agreement with AC Immune	Jan. 22	CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc	Jan. 22	CI
AC Immune to Regain Global Rights to Crenezumab and Semorinemab	Jan. 22	AQ
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases	Jan. 03	CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases	Jan. 03	AQ
AC Immune : Underwriting Agreement - Form 6-K	Dec. 19	PU
AC Immune's Targeted Anti-PTau Active Immunotherapy for Alzheimer's disease Advances into Phase 2b Trial	Dec. 18	AQ
AC Immune Announces Pricing of Underwritten Offering of Common Shares	Dec. 18	AQ
AC Immune SA(NasdaqGM:ACIU) added to NASDAQ Biotechnology Index	Dec. 18	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 15	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Dec. 15	MT
AC Immune Announces Pricing of Underwritten Offering of Common Shares	Dec. 15	AQ
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial	Dec. 15	CI
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial	Dec. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AC Immune SA

Equities

ACIU

CH0329023102

Summary

Filters